Real‐world outcomes of addition of insulin glargine 300 U/ mL (Gla‐300) to glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) therapy in people with type 2 diabetes: The DELIVER‐G study
Diabetes Obesity and Metabolism2022Vol. 24(8), pp. 1617–1622
Citations Over TimeTop 24% of 2022 papers
Timothy S. Bailey, Jasvinder Gill, Merwyn Jones S., Laxmi Shenoy, Charlie Nicholls, Jukka Westerbacka
Abstract
In US real-world clinical practice, adding Gla-300 to GLP-1RA significantly improved glycaemic control without significantly increasing hypoglycaemia in PWD2. Further research into the effect of adding Gla-300 to GLP-1RA therapy is warranted.
Related Papers
- → Endogenous glucagon‐like peptide (GLP)‐1 as alternative for GLP‐1 receptor agonists: Could this work and how?(2023)17 cited
- → Glucagon-like peptide-1 (GCG; GLP-1); GLP-1 receptor (GLP1R; GLP-1R)(2009)1 cited
- → The role of glucagon like peptide - 1 (GLP-1) receptor agonists in the treatment of type 2 diabetes mellitus(2019)
- → Decision letter for "Efficacy and safety of high‐dose GLP ‐1, GLP ‐1/ GIP and GLP ‐1/glucagon receptor agonists in type 2 diabetes"(2021)
- → Review for "Efficacy and safety of high‐dose GLP ‐1, GLP ‐1/ GIP and GLP ‐1/glucagon receptor agonists in type 2 diabetes"(2021)